Radiant Acupuncture

I have a new friend that has joined my Lucky Kitty gang.

https://www.facebook.com/share/1FkH6jpiPp/?mibextid=wwXIfr

German researchers have introduced a groundbreaking therapy that has permanently restored insulin production in a large percentage of Type 1 diabetes patients. The treatment uses a patient’s own stem cells, reprogramming them into new insulin-producing beta cells and implanting them back into the pancreas. Early trials show that more than 80% of patients became fully insulin-independent within months — with healthy, natural glucose control maintained for years. The therapy also includes targeted immunotherapy to stop the autoimmune attack that originally destroyed the pancreas, making the cure long-lasting instead of temporary.

But while this treatment is fully or heavily covered in Germany under universal healthcare, the situation in the U.S. is drastically different. American patients face out-of-pocket costs that can exceed $40,000 because insurers classify the therapy as “experimental.” For many, traveling abroad becomes the only realistic option. This sharp contrast has reignited global debates around healthcare access, medical pricing, and the ongoing conflict between life-saving cures and long-term pharmaceutical profit models.

https://www.facebook.com/share/p/17gTzC7nZc/?mibextid=wwXIfr

🚨 Lupus finally has a clear culprit.

It's a common virus carried by 95% of us.

A groundbreaking study has finally revealed the mechanism linking the Epstein-Barr virus (EBV)—carried by more than 95% of adults worldwide—to lupus, a debilitating autoimmune disease.

For decades, researchers suspected a connection between the two, but the biological trigger remained elusive.

Now, scientists at Stanford Medicine have identified how EBV can transform the immune system’s B cells into rogue antigen-presenters, activating a cascade of immune responses that ultimately causes the body to attack itself. In lupus patients, EBV-infected B cells are dramatically more common—1 in every 400 cells compared to fewer than 1 in 10,000 in healthy people. This activity awakens self-attacking B cells and killer T cells, causing the systemic inflammation and tissue damage seen in lupus.

The discovery marks a major leap in understanding lupus and possibly other autoimmune diseases like multiple sclerosis, which has also been linked to EBV. “We think it applies to 100% of lupus cases,” said senior author Dr. William Robinson. While EBV infection is nearly universal, only a fraction of those infected develop lupus—likely due to genetic differences, environmental factors, or variations in virus strains. Identifying the exact EBV-related trigger opens a path to more targeted therapies and even preventive strategies in the future. As the study’s authors suggest, this could be one of the most significant breakthroughs in autoimmune research in decades.

Source: Science Translational Medicine. Nov 2025.